Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $28,640,230.85 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 562,345 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $50.93, for a total transaction of $28,640,230.85. Following the completion of the transaction, the chief executive officer now owns 9,457,283 shares of the company's stock, valued at $481,659,423.19. This trade represents a 5.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Tempus AI Stock Performance

Shares of TEM stock traded up $0.24 on Friday, reaching $49.10. The company had a trading volume of 9,329,504 shares, compared to its average volume of 4,780,820. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The business's 50-day moving average is $54.30 and its 200 day moving average is $52.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. First Horizon Advisors Inc. bought a new position in Tempus AI in the 3rd quarter valued at approximately $30,000. Operose Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $25,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC grew its position in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after buying an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI in the 4th quarter valued at $49,000. Institutional investors own 24.22% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

TEM has been the subject of several research analyst reports. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and upped their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Piper Sandler dropped their price target on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a research report on Tuesday. Wolfe Research downgraded shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Needham & Company LLC upped their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Finally, Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Tempus AI presently has a consensus rating of "Moderate Buy" and an average price target of $61.18.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.